Ipamorelin 10mg

Each lot of Ipamorelin is supplied lyophilized and is characterized analytically prior to release:

• Purity: reversed-phase HPLC, ≥99% as reported on the lot-specific COA.
• Identity: confirmed by mass spectrometry (MS) against the expected molecular mass of the pentapeptide sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂.
• CAS Registry Number: 170851-70-4.
• Lot documentation: net peptide content, HPLC chromatogram, and MS values are reported as lot-specific values on the COA accompanying each unit.

These analyses are analytical characterizations of identity and purity only. They are not a measure of biological activity, safety, or fitness for any application. For research use only, not for human use.

A Certificate of Analysis is available per production lot, documenting HPLC purity and mass-spectrometry identity confirmation.

View Certificates of Analysis →

For Research Use Only · Not for human or veterinary use · Not for diagnostic or therapeutic use.

References to clinical phases/studies describe the compound in independent third-party literature (e.g., ClinicalTrials.gov, PubMed) and do not represent claims, testing, or approval by Zynix Biolab.

Ipamorelin is a synthetic pentapeptide with the reported sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂ (CAS 170851-70-4). In the published literature it has been characterized as a selective agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a / ghrelin receptor) and is classified among the growth hormone-releasing peptides (GHRPs).

The compound was first described in the preclinical literature by Raun and colleagues (European Journal of Endocrinology, 1998), where it was reported as a growth hormone secretagogue that, in the models studied, released growth hormone without significantly elevating ACTH or cortisol relative to GHRH stimulation — a selectivity profile examined in subsequent third-party work. It has since been the subject of in-vitro receptor-binding studies and in-vivo animal models, including a rodot study of longitudinal bone growth (Johansen et al., 1999).

In third-party clinical research conducted by other organizations, ipamorelin has been investigated as a ghrelin-receptor agonist for the recovery of gastrointestinal function following abdominal surgery (postoperative ileus), as registered on ClinicalTrials.gov under identifier NCT00672074. References to these external study phases describe research by third parties and do not represent testing, validation, or approval by Zynix Biolab. For research use only, not for human use.

For Research Use Only · Not for human or veterinary use · Not for diagnostic or therapeutic use.

In the published scientific literature, ipamorelin has been examined as a tool compound in laboratory and preclinical research contexts, including:

• In-vitro studies of GHS-R1a (ghrelin receptor) binding and agonist activity and associated intracellular signaling pathways.
• Investigations of growth hormone-releasing potency and selectivity relative to other secretagogues in cell-based and animal models.
• Animal-model research on somatotropic-axis dynamics, including studies of longitudinal bone growth and body-weight endpoints in rodents.
• Use as a reference / comparator GHRP in structure-activity and receptor-pharmacology studies.

These descriptions are provided for scientific context only, summarizing research reported by third parties. This product is not for human use, diagnostic use, or therapeutic use.

General laboratory handling guidance for the lyophilized research material:

• Storage (lyophilized): store at -20°C, protected from light and moisture; minimize freeze-thaw cycles.
• Reconstitution: for laboratory preparation, reconstitute with bacteriostatic or sterile water by adding solvent slowly down the vial wall and swirling gently (do not shake) until fully dissolved.
• Reconstituted storage: keep refrigerated at 2–8°C and use within the working window established by the laboratory; aliquot to limit repeated freeze-thaw.
• PPE: handle with appropriate personal protective equipment (gloves, eye protection, lab coat) under standard laboratory practice.

This handling information is general laboratory guidance and is not a dosing or administration instruction. For research use only — not for human use.

For Research Use Only · Not for human or veterinary use · Not for diagnostic or therapeutic use.

• Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. PMID: 9849822. DOI: 10.1530/eje.0.1390552
• Johansen PB, Nowak J, Skjærbæk C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106–113. PMID: 10373343
• ClinicalTrials.gov. Safety and Efficacy of Ipamorelin for the Treatment of Postoperative Ileus. Identifier NCT00672074

These references are provided for scientific context only and are not claims by Zynix Biolab.